Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

181. Interruption in Use of the New Class of Direct Thrombin Inhibitors and Factor Xa Inhibitors is Not Indicated for the Anticoagulated Patient Undergoing Simple Dental Procedures

Interruption in Use of the New Class of Direct Thrombin Inhibitors and Factor Xa Inhibitors is Not Indicated for the Anticoagulated Patient Undergoing Simple Dental Procedures UTCAT2828, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Interruption in Use of the New Class of Direct Thrombin Inhibitors and Factor Xa Inhibitors is Not Indicated for the Anticoagulated Patient Undergoing Simple Dental Procedures Clinical (...) were proposed: Interruption of rivaroxaban and dabigatran is not indicated. The only recommendation regarding their regimen is for the patient to not take their medication 1-3 hours prior to their appointment. Patient needs to be informed that bleeding is normal because their anticoagulation medication was not ceased. #2) Firriolo/2012 Narrative Review Key results If kidney function is normal, and there are no other risks for compromised hemostasis, then discontinuation of Xarelto and Pradaxa

UTHSCSA Dental School CAT Library2015

182. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments.

Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Antithrombotic drugs, which include antiplatelet and anticoagulant therapies, prevent and treat many cardiovascular disorders and, as such, are some of the most commonly prescribed drugs worldwide. The first drugs designed to inhibit platelets or coagulation factors, such as the antiplatelet clopidogrel and the anticoagulant warfarin, significantly reduced the risk of thrombotic events (...) variability in their antithrombotic effects than previous antithrombotic drugs. Treatment options now include the next-generation antiplatelet drugs prasugrel and ticagrelor, and, in terms of anticoagulants, inhibitors that directly target factor IIa (dabigatran) or Xa (rivaroxaban, apixaban, edoxaban) are available. In this Series paper we review the pharmacological properties of these most commonly used oral antithrombotic drugs, and explore the development of antiplatelet and anticoagulant therapies

Lancet2015

183. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs.

Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. In patients with non-valvular atrial fibrillation, oral anticoagulation with vitamin K antagonists reduces the risk of stroke by more than 60%. But vitamin K antagonists have limitations, including causing serious bleeding such as intracranial haemorrhage and the need for anticoagulation monitoring. In part related to these limitations, they are used in only about half (...) of patients who should be treated according to guideline recommendations. In the past decade, oral agents have been developed that directly block the activity of thrombin (factor IIa), as well as drugs that directly inhibit activated factor X (Xa), which is the first protein in the final common pathway to the activation of thrombin. These novel non-vitamin K antagonist oral anticoagulants (NOACs) have been shown to be at least as good as warfarin for stroke prevention in atrial fibrillation and they have

Lancet2015

185. Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran ? first line

Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran ? first line Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran – first line Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran – first line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NIHR HSC. Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran – first line . Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2015 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Anticoagulants; Benzimidazoless; Blood Coagulation; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Thromboembolism Language Published English Country of organisation England English

Health Technology Assessment (HTA) Database.2015

186. Should Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex) Receive Oral Anticoagulation?

Should Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex) Receive Oral Anticoagulation? 25677422 2015 02 14 2015 04 06 2015 02 14 1558-3597 65 7 2015 Feb 24 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? 635-42 10.1016/j.jacc.2014.11.046 S0735-1097(14)07391-4 Although the CHA2DS2-VASc (...) score = 1 [males] or 2 [females]) and the impact of different component risk factors. We used the National Health Insurance Research Database in Taiwan. Among 186,570 AF patients not on antiplatelet or anticoagulant therapy, we evaluated males with a CHA2DS2-VASc score of 1 and females with a CHA2DS2-VASc score of 2. The clinical endpoint was the occurrence of ischemic stroke. Among 12,935 male AF patients with a CHA2DS2-VASc score of 1, 1,858 patients (14.4%) experienced ischemic stroke during

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

187. New/Novel Oral Anticoagulants (NOACS): Comparison and Frequently-Asked Questions

New/Novel Oral Anticoagulants (NOACS): Comparison and Frequently-Asked Questions © 2015 Thrombosis Canada Page 1 of 7 NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY- ASKED QUESTIONS OBJECTIVES: ? To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. ? To address frequently-asked questions regarding NOACs. BACKGROUND: NOACs, which consist of apixaban, dabigatran and rivaroxaban, are being used increasingly for the prevention (...) of the procedure; consideration can also be given to the use of the pro-hemostatic tranexamic acid mouthwash before and after the procedure. Alternatively, the patient can skip one day’s dose of the NOAC before the procedure and resume the NOAC on the evening after the procedure. For the management of patients who require other procedures or surgery, see the Clinical Guide: New/Novel Oral Anticoagulants (NOACs): Peri-Operative Management. What if the patient has a prosthetic heart valve? In patients

Thrombosis Interest Group of Canada2015

188. Do patients with an asymptomatic sub-segmental pulmonary embolism need anticoagulation therapy?

Do patients with an asymptomatic sub-segmental pulmonary embolism need anticoagulation therapy? BestBets: Do patients with an asymptomatic sub-segmental pulmonary embolism need anticoagulation therapy? Do patients with an asymptomatic sub-segmental pulmonary embolism need anticoagulation therapy? Report By: Hyun Choi - CT3 Search checked by Christopher Morgan - Institution: Central Manchester University Hospitals NHS Foundation Trust, University Of Manchester Date Submitted: 27th November 2010 (...) Date Completed: 5th January 2015 Last Modified: 5th January 2015 Status: Green (complete) Three Part Question [In an asymptomatic patient with small subsegmental pulmonary embolism] does [anticoagulation therapy or no treatment] lead to [reduced mortality and a lower rate of recurrent venous thromboembolism?] Clinical Scenario A 49 year old male, who was previously fit and well, attended the Emergency Department as a trauma patient after being involved in a road traffic collision. He underwent

BestBETS2015

189. Praxbind (idarucizumab) - For use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa?s blood-thinning effects

Praxbind (idarucizumab) - For use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa?s blood-thinning effects Praxbind (idarucizumab) U.S. Department of Health and Human Services Search FDA Submit search Praxbind (idarucizumab) Vraylar (Cariprazine) Company: Boehringer Ingelheim Pharmaceuticals Application No.: 761025 Orig1 Approval Date: October 16, 2015 Persons with disabilities having problems accessing

FDA - Drug Approval Package2015

190. Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. An analysis of the AMPLIFY-EXT trial

Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. An analysis of the AMPLIFY-EXT trial 26446706 2015 12 22 2016 09 26 2015 12 22 0340-6245 115 1 2016 Jan Thrombosis and haemostasis Thromb. Haemost. Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. An analysis of the AMPLIFY-EXT trial. 161-8 10.1160/TH15-07-0606 Treatment with apixaban versus placebo for 12 months significantly reduced (...) Method Drug Administration Schedule Factor Xa Inhibitors administration & dosage adverse effects Female Hemorrhage chemically induced Hospitalization Humans Length of Stay Male Middle Aged Pyrazoles administration & dosage adverse effects Pyridones administration & dosage adverse effects Recurrence Risk Factors Time Factors Treatment Outcome Venous Thromboembolism diagnosis drug therapy mortality Apixaban extended anticoagulation hospitalisation venous thromboembolism 2015 07 30 2015 09 18 2015 10 9

EvidenceUpdates2015

191. Randomised controlled trial: An IVC filter and anticoagulation for 3?months is unlikely to show a benefit over anticoagulation alone for high-risk patients with acute pulmonary embolism

Randomised controlled trial: An IVC filter and anticoagulation for 3?months is unlikely to show a benefit over anticoagulation alone for high-risk patients with acute pulmonary embolism An IVC filter and anticoagulation for 3 months is unlikely to show a benefit over anticoagulation alone for high-risk patients with acute pulmonary embolism | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here An IVC filter and anticoagulation for 3 months is unlikely to show a benefit over anticoagulation alone for high-risk patients with acute pulmonary embolism Article

Evidence-Based Medicine (Requires free registration)2015

192. Randomised controlled trial: Interruption of all anticoagulation is non-inferior to the use of short-term parenteral bridging in patients with atrial fibrillation undergoing invasive procedures

Randomised controlled trial: Interruption of all anticoagulation is non-inferior to the use of short-term parenteral bridging in patients with atrial fibrillation undergoing invasive procedures Interruption of all anticoagulation is non-inferior to the use of short-term parenteral bridging in patients with atrial fibrillation undergoing invasive procedures | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Interruption of all anticoagulation is non-inferior to the use of short-term parenteral bridging in patients with atrial fibrillation undergoing invasive

Evidence-Based Medicine (Requires free registration)2015

193. The Use of a Mobile Compression Device Following a Lower Extremity Total Joint Arthroplasty Can Provide Venous Thromboembolic Prophylaxis Comparable to Current Pharmacological Anticoagulation Protocols

The Use of a Mobile Compression Device Following a Lower Extremity Total Joint Arthroplasty Can Provide Venous Thromboembolic Prophylaxis Comparable to Current Pharmacological Anticoagulation Protocols "The Use of a Mobile Compression Device Following a Lower Extremity Tot" by McKel A. Roskelley < > > > > > Title Author Date of Award Summer 8-8-2015 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers, PA-C, MS Rights (...) . Abstract Background: Venous thromboembolisms (VTE) are an important complication following arthroplasty of the knees and hips, and proper prophylaxis protocol continues to be a source of debate in the medical community. In the past patients have been managed with pharmaceutical anticoagulants (eg, LMWH), mechanical compression, or a combination of the two. The inability to use mechanical compression on an outpatient basis has limited its use in the past, but the introduction of an outpatient mobile

Pacific University EBM Capstone Project2015

194. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications

Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications Interventional Spine and Pain Procedures in Patients on Anti... : Regional Anesthesia and Pain Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. You currently have no recent searches Enter your Email address: Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your (...) ) 11th Annual Pain Medicine Meeting exhorted that existing ASRA guidelines for regional anesthesia in patients on antiplatelet and anticoagulant medications were insufficient for their needs. Those surveyed agreed that procedure-specific and patient-specific factors necessitated separate guidelines for pain and spine procedures. In response, ASRA formed a guidelines committee. After preliminary review of published complication reports and studies, committee members stratified interventional spine

American Society of Regional Anesthesia and Pain Medicine2015

195. The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score

The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score 25086251 2014 11 05 2015 02 24 2014 11 05 1931-3543 146 5 2014 Nov Chest Chest The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using (...) the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide cohort study. 1337-46 10.1378/chest.14-0533 Our objective was to determine stroke and thromboembolism event rates in patients with atrial fibrillation (AF) classified as "low risk" using the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) score and to ascertain event rates in this group in relation to the stroke risk assessment advocated in the 2012 European Society of Cardiology (ESC) guidelines (based

EvidenceUpdates2014

196. Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban.

Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban. Use of PER977 to reverse the anticoagulant effect of edoxaban. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 25371966 Format MeSH and Other Data (...) E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2014 Nov 27;371(22):2141-2. doi: 10.1056/NEJMc1411800. Epub 2014 Nov 5. Use of PER977 to reverse the anticoagulant effect of edoxaban. 1 , , , , , , , , . 1 Hofstra North Shore-LIJ School of Medicine, Hempstead, NY ansellje@gmail.com. PMID: 25371966 DOI: [Indexed for MEDLINE] Free full text Publication

NEJM2014 Full Text: Link to full Text with Trip Pro

197. Rivaroxaban 2.5 mg (Xarelto): no justification for using this anticoagulant after an acute coronary syndrome

Rivaroxaban 2.5 mg (Xarelto): no justification for using this anticoagulant after an acute coronary syndrome Prescrire IN ENGLISH - Spotlight ''Rivaroxaban 2.5 mg (Xarelto°): no justification for using this anticoagulant after an acute coronary syndrome'', 1 October 2014 {1} {1} {1} | | > > > Rivaroxaban 2.5 mg (Xarelto°): no justification for using this anticoagulant after an acute coronary syndrome Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |  (...)  |   |   |   |   |   |   |   |  Spotlight Rivaroxaban 2.5 mg (Xarelto°): no justification for using this anticoagulant after an acute coronary syndrome FEATURED REVIEW It has not been demonstrated that adding rivaroxaban to aspirin alone or to aspirin plus clopidogrel benefits patients who have had an acute coronary syndrome. The risk of serious and fatal bleeds is probably underestimated. Caution dictates that rivaroxaban should

Prescrire2014

198. Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores.

Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores. OBJECTIVE: To develop and validate risk algorithms (QBleed) for estimating the absolute risk of upper gastrointestinal and intracranial bleed for patients with and without anticoagulation aged 21-99 years in primary care. DESIGN: Open cohort study using routinely collected data from general practice linked to hospital episode statistics data (...) a valid Townsend score for deprivation and those prescribed anticoagulants in the 180 days before study entry. RISK FACTORS: Candidate variables recorded on the general practice computer system before entry to the cohort, including personal variables (age, sex, Townsend deprivation score, ethnicity), lifestyle variables (smoking, alcohol intake), chronic diseases, prescribed drugs, clinical values (body mass index, systolic blood pressure), and laboratory test results (haemoglobin, platelets). We also

BMJ2014 Full Text: Link to full Text with Trip Pro

199. Anticoagulation therapy versus placebo for pulmonary hypertension.

Anticoagulation therapy versus placebo for pulmonary hypertension. BACKGROUND: Elevation of pulmonary pressure is no longer a rare disease, given its multifactorial etiology. However data on the actual incidence of this condition are still limited, and controversies regarding its management are ongoing. Use of anticoagulation in the management of pulmonary hypertension is based on the presence of in situ thrombosis in the patient with pulmonary arterial hypertension (PAH) and on retrospective (...) evidence of clinical benefit. Current practice is dependent mostly on expert opinion and individualised experience. The real benefit of its use in different types of pulmonary hypertension is still debatable, and the therapeutic target of the international normalised ratio (INR) among treated patients remains inconclusive. Adverse outcomes associated with anticoagulants are significant and can include fatal haemorrhage. Justification for the use of this intervention requires critical evaluation

Cochrane2014

200. Antiplatelet and anticoagulant treatments for unstable angina/non?ST elevation myocardial infarction

Antiplatelet and anticoagulant treatments for unstable angina/non?ST elevation myocardial infarction Antiplatelet and anticoagulant treatments for unstable angina/non–ST elevation myocardial infarction Antiplatelet and anticoagulant treatments for unstable angina/non–ST elevation myocardial infarction Melloni C, Jones WS, Washam JB, Hasselblad V, Mayer SB, Halim S, Subherwal S, Alexander K, Kong DF, Heidenfelder BL, Irvine RJ, Wing L, Dolor RJ Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Melloni C, Jones WS, Washam JB, Hasselblad V, Mayer SB, Halim S, Subherwal S, Alexander K, Kong DF, Heidenfelder BL, Irvine RJ, Wing L, Dolor RJ. Antiplatelet and anticoagulant treatments for unstable angina/non–ST elevation myocardial infarction. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 129

Health Technology Assessment (HTA) Database.2014